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Outcome of living unrelated (commercial) renal transplantation. Although transplantation offers the best option for
Background. Due to inadequate cadaveric and living related rehabilitation, many patients with end-stage renal dis-
organ supply, many end-stage renal disease patients go to Third
ease (ESRD) do not have an opportunity for this type ofWorld countries for commercial transplantation, although the
treatment, mainly because of organ shortage. In Westernhigh risk of complications is well established and ethical argu-
ments debate this practice. countries, cadaveric organ donations have reached to a
Methods. The midterm outcome of 115 patients who had steady state that is far from coping with the demand.
been commercially transplanted in various countries and ad-
Consequently, the number of ESRD patients on trans-mitted to our center for post-transplant care and follow-up
plant waiting lists is increasing progressively [1]. Thebetween 1992 and 1999 was retrospectively analyzed. Data
considering the transplantation practice and post-transplant situation is even worse in developing countries [2]. Since
course were collected from the patient files. Outcome of these many ESRD patients do not have suitable living relatedpatients was compared with those with a living related trans-
donors, they seek for alternative donor sources; thus,plant performed at our center.
Results. The patients (91 male and 24 female; mean age of living unrelated transplantation (LURT) is considered
42  12 years) were transplanted in India (N  106), Iraq [3–7]. Indeed, in the United States, the rate of increase
(N  7), and Iran (N  2). The mean follow-up period was
in LURT is greater than in cadaveric and living related64.5  23.9 months. Post-transplant course was complicated
transplantations [1].by numerous surgical and/or medical complications, and many
of the latter were unconventional infections caused by malaria, On the other hand, since many patients cannot find
invasive fungal infections, and pneumonia due to various op- suitable unrelated donors in their own countries due to
portunistic pathogens. Overall, 52 patients still have function-
a variety of reasons (social, legal, financial, ethical, etc.),ing allografts, while 22 lost their grafts, 20 died, and 21 were
they travel to Third World countries for the procedure,lost to follow-up. Graft survival rates at two, five, and seven
years were 84, 66, and 53%, respectively, for the study group, which also means paid transplantation. Paid (in other
while it was 86, 78, and 73% for living related transplantations words, commercial) transplantation has been consideredperformed at our center (P  0.036). Patient survival rates for
by many authors to be strictly not ethical [8–12], whereasthe same periods were 90, 80, and 74% for the study group
and 90, 85, and 80% for the living related transplantations (P others claim that the ethical side of this type of trans-
0.53). plantation should be reopened for discussion [13–15].
Conclusions. Besides the ongoing ethical debate, commer- Commercial transplantation is not only controversialcial transplantation carries a high risk of unconventional com-
for ethical aspects, but has been reported to result inplications, and despite that the patient survival rate is compara-
ble, graft survival is worse than conventional living related serious complications in the postoperative period that
transplantations at the midterm. cause high rates of morbidity and mortality [11, 15–20],
and it also carries the risk of a negative effect on local
transplant programs [8, 16, 21]. However, despite these
arguments, unethical transplantation is an ongoing en-
tity, and transplant physicians are frequently faced withKey words: organ transplant, end-stage renal disease, transplant ethics,
the problem of treating complications of this type ofcadaveric organ donation, living unrelated transplantation.
transplantation.
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METHODS Patient and graft survival rates of these patients were
compared with living related donor transplant recipientsTransplant recipients who received unrelated trans-
whose transplantation was performed at our center.plantations in India, Iraq, and Iran and were admitted
Patient and graft survival rates were analyzed by usingto our center for post-transplant follow-up between 1992
the Kaplan-Meier test.and 1999 comprised the patient population of this analysis.
All of the patients were Turkish and had been living
and dialyzed in Turkey, who traveled to these centers on RESULTS
their own initiative and returned after transplantation.
Of the 115 patients [91 male and 24 female; mean ageWhile most of the patients were admitted to our clinic
of 42 12 (range 19 to 73) years], 106 were transplantedwithin the first two to four weeks after the operation,
in India, 7 in Iraq, and 2 in Iran. Most (N  86) of thesome others had been admitted to other clinics first and
patients were admitted until the end of 1994; however,later were referred to our center. All donor organs were
although decreased in number, the patient flow contin-supplied by brokers. A detailed description of the prac-
ued thereafter (Fig. 1). The mean follow-up period wastice has been reported previously [16].
64.5  23.9 (range of 1 to 91) months.Information about transplant operation arrangements,
Three of the patients were admitted with primary non-costs, and hospital facilities was supplied by the patients.
functioning allografts. At admission, mean serum creati-The preoperative clinical findings and laboratory results
nine was 2.0  1.6 (range 0.9 to 10.0) mg/dL, and thewere obtained from the hospital files that the patients
mean serum cyclosporine level was 390.1  453.0 (rangebrought; however, only some of them had this type of
35 to 3500) ng/mL by TDx.documentation.
Taken as a whole, the patients were hospitalized 121Taken as whole, there were 115 commercial transplant
times, and 51 (42%) of these hospitalizations took placerecipients. The patients who did not return to the clinic
during the first three post-transplant months. Hospital-during the last 12 months were considered as lost to
izations were indicated for treatment of the followingfollow-up. While the last clinical data present in the files
of these patients were evaluated, they were not included surgical and medical complications.
in the analysis of allograft and patient survival rates.
Surgical complicationsPatients presenting with an uneventful post-transplant
clinical course and normal kidney function with stable We found the following initial surgical complications:
clinical and laboratory findings were followed at the out- severe wound infection (N  5; considering these pa-
patient clinic, whereas those with medical and/or surgical tients, there was a gauze pad left in the wound of one
complications were hospitalized. patient and eventration in another), lymphocele (N 6),
For each patient, blood biochemistry, urinalysis, creat- renal artery thrombosis (N  1), urinary fistula (N  3),
inine clearance, electrocardiography, chest x-ray, plasma hydrocele (N  5), pancreatitis (N  1), and decubitus
cyclosporine A level determinations by fluorescent po- ulcer (N  1). Late surgical complications were urethral
larization immunoassay (TDx), drainage fluid (if pres- stenosis in two patients and hydrocele in one.
ent) examinations, sputum and urine cultures, serological
tests concerning cytomegalovirus, hepatitis B, C, herpes Medical complications
simplex and human immunodeficiency viruses, and thick Medical complications were noted frequently and are
and thin blood film examinations for plasmodia were
summarized in Table 1. Remarkably, unconventional in-
carried out. Additionally, the scintigraphic and ultra-
fectious complications were observed in 15 recipients.sonographic examinations of the allograft, and percuta-
Of these, all 10 cases of malaria responded to medicalneous transplant biopsies were performed as needed.
therapy. Two patients with systemic and central nervousImmunosuppressive medications that were started in
system aspergillosis died despite therapy with amphoter-the original transplant center were kept the same; how-
icin B, whereas the third one with urinary tract aspergil-ever, necessary adjustments were made in the presence
losis improved with treatment. The patients with trans-of any complication. Intravenous methylprednisolone with
plant and rhinocerebral mucormycosis died despite medicala daily dose of 500 mg for three consecutive days was
therapy with amphotericin B and allograft nephrectomyadministered as a first line of antirejection therapy, and
to the former. Interestingly, no unconventional compli-then if there was no response, antilymphocyte globulin
cation was noted during the last three years. Eight and(ALG; Pressimmun-Hoechst, Frankfurt am Main, Ger-
69 of the patients were serologically positive for hepatitismany) was given with a daily dose of 20 mg/kg for 14 to
B and C viruses, respectively. Two patients with hepatitis21 days.
B and three patients with hepatitis C were known to beOther medical and/or surgical complications were
serologically negative before the transplant operation,treated accordingly and supportive dialysis was performed
if needed. and infection was noted in the early post-transplant pe-
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Fig. 1. Countries where transplantations were
performed and patient flow by years.
Table 1. Medical complications observed in commercial renal transplant recipients
Infectious complications Other complications
Type N Type N
Unconventional infections Acute rejectionsb 8
Malaria 10 Cardiovascular
Rhinocerebral mucormycosis 1 Ischemic heart diseasec 6
Transplant mucormycosis 1 Congestive heart failure and severe electrolyte disturbance 2
Systemic aspergillosis 1 Endocarditis 1
Cerebral aspergillosis 1 Cardiomyopathy 1
Urinary tract aspergillosis 1 Atrial fibrillation 1
Unconventional pneumonia Other
Pneumocystis carinii pneumonia 3 Post-transplant diabetes mellitusd 11
Nocardia pneumonia 1 Erythrocytosis 11
Cytomegalovirus pneumonia 1 Cyclosporine nephrotoxicity 7
Legionella pneumonia 1 Late acute rejection 5
Tuberculosis Kaposi sarcoma 5
Tuberculosis meningitis 1 Aseptic necrosis 5
Intestinal tuberculosis complicated by perforation 1 Cataract 3
Tuberculosis osteomiyelitis 1 Gastrointestinal bleeding 1
Sepsis (tuberculosis) 1 Cerebrovascular event 1
Granulomatous hepatitis 1 Steroid myopathy 1
Other infections Cortical necrosis 1
Urinary tract infections 19 Cyclosporine nephro-, hepato-, neurotoxicity 1
Pneumonia 6 Genital condylomata 1
Chronic active hepatitisa 5
Zona zoster 5
Transplant pyelonephritis 5
Epididimitis 1
a Secondary to C and B hepatitis in 3 and 2 patients, respectively
b Five-therapy resistant
c Four of which were myocardial infarctions
d One with ketoacidosis
riod. Of these five patients, three developed cirrhosis and functioning grafts are being followed in our center, with
a mean last serum creatinine value of 2.43  2.22 (rangetwo were diagnosed with chronic active hepatitis.
Taken as a whole, 20 patients died, 11 with functioning 0.7 to 10) mg/dL.
Causes of death were as follows: infections, 7 (pneu-allografts. Twenty-two patients lost their grafts. Twenty-
one patients were lost to follow-up, and 52 patients with monia, 1; generalized aspergillosis, 1; cerebral aspergil-
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Fig. 2. Graft survival rates in living unrelated
(commercial) transplantations in different coun-
tries (dashed line) and living-related donor
transplantations performed at the Hospital of
Istanbul School of Medicine (solid line).
losis, 1; candida sepsis, 1; transplant mucormycosis, 1; 25]. Therefore, at first glance conventional LURT seems
to be an appropriate form of renal replacement therapyrhinocerebral mucormycosis, 1; generalized tuberculosis,
for ESRD. However, the same considerations cannot be1); cardiovascular complications, 4; hepatic failure, 3;
applied to unconventional (commercial) LURT, since inand other complications, 6. Causes of graft failure were
many series the results are not as favorable, due to surgi-chronic allograft nephropathy (N  15), therapy resis-
cal and medical problems [18, 20, 26, 27].tant acute rejection (N  5), de novo or recurrent glo-
Surgical complications following these transplanta-merulonephritis (N  1), and transplant pyelonephritis
tions have been described as the major cause of morbid-(N  1).
ity and mortality in both the early and late post-trans-Graft survival rates at two, five, and seven years were
plant periods [11, 28]. In parallel with those reports, ourfound to be 84, 66, and 53%, respectively, for the LURT
present analysis found that the rate of surgical complica-group, whereas they were 86, 78, and 73% for the patients
tions was quite high and some were very serious and un-transplanted from living related donors at the Istanbul
conventional, such as a retained sponge in the woundSchool of Medicine (P  0.036; Fig. 2). Patient survival
and eventration. Although the reason for these complica-rates at two, five, and seven years were 90, 80, and 74%,
tions is obscure, very probably it is due to surgical meth-respectively, for the LURT group, while they were 90, 85,
ods that do not meet the current standards of trans-and 80% during the same periods for the living related
plantation practice. Chugh and Jha from India reportedtransplantations performed at our center (P  0.53;
that some of these unrelated donor transplantations wereFig. 3).
performed by unscrupulous doctors in mushrooming,
private back-street clinics, and that many of these clinics
DISCUSSION lacked the most basic sanitary facilities [9].
Both medical and ethical aspects should be considered In the present analysis the rate of medical complica-
when discussing LURT. tions also was very high. Many were unconventional in-
From medical point of view, in conventional situations fections such as malaria and invasive fungal infections,
it is well established that LURT graft and patient survival and were similar to those described previously [17–19,
rates are better than cadaveric, and are comparable with 26, 29–33]. Another interesting article from Chugh et al
reported that among 310 recipients of living related renalthose of living related donor transplantations [3, 4, 22–
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Fig. 3. Patient survival rates in living unre-
lated (commercial) transplantations in differ-
ent countries (dashed line) and living related
donor transplantations performed at the Hos-
pital of Istanbul School of Medicine (solid
line) (P  0.53).
transplants, systemic fungal infections including crypto- outcome of the patients with commercial transplanta-
tions with both unfavorable [18, 20, 35] and favorablecoccosis, candidiasis, mucormycosis, aspergillosis, and
mixed cryptococcal-aspergillus infections were observed [11, 17, 36] results. In the present analysis, when com-
pared with living related transplantations performed atin 6.1% of the patients [34]. Both in the present and
other analyses [18, 30], most of the complications oc- our center, both graft and patient survival rates were
lower, although the latter did not reach statistical signifi-curred within the first three post-transplant months, sug-
gesting that very close early follow-up of these patients cance. The lower graft survival rate may be due to a
poorer HLA matching as compared with living relatedis mandatory.
Remarkably, in the present series there were five pa- transplantations performed at our center. When consid-
ering the nonsignificant patient survival rate found intients who were complicated with chronic liver disease
(3 cirrhosis and 2 chronic active hepatitis). Unfortu- our study, three issues must be taken into account. First,
only the outcomes of the patients who survived after thenately, the two with hepatitis are progressing to cirrhosis.
Transmission of hepatitis viruses during or soon after the transplant operation and had the opportunity to return
to our country were evaluated. We had been informedoperation has been described in other reports [17, 30,
31, 35], and chronic liver disease was found to be the only that there were patients who died during or early after
the operation, and these are not included in the analysis.complication associated with death in a multicenter study
analyzing the long-term outcome of these patients [17]. Second, three patients were already complicated with
cirrhosis and a further two with chronic active hepatitisIt is our [16] and other authors’ [9, 29, 34] impression
that many of the complications found in LURT probably (who unfortunately are on the way to developing cirrho-
sis). While these patients have functioning renal allo-resulted from unhealthy donors and/or poor hygienic
conditions. In both situations, it is obvious that if the grafts for the time being, they are candidates for a poor
long-term prognosis, and this will adversely affect thecurrent standards of medicine had been applied, these
complications might have been prevented. On the other final outcome data. Finally, a large number of patients
were lost to follow-up and it is quite probable that thesehand, it should be emphasized that the frequency of
life-threatening opportunistic infections has decreased patients either lost their grafts or died. It may be that
we were not informed of their final outcome because ofin recent years [17].
There are contradictory reports regarding the final the guilty feelings of the patients and/or their families.
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Therefore, the message of the present analysis carries about the unconventional complications as well as the
ongoing ethical debate, thus stimulating interest in find-the risk of being too optimistic, and the real outcome
could be worse. ing the correct solution.
In conclusion, despite somewhat acceptable but poorThe ethics of LURT are more complicated than the
medical aspects. While many transplant physicians sug- results of the present analysis at the midterm, the actual
final outcome of commercial transplantation may begest that the organ trade is unethical and unacceptable
[8, 10–12, 27, 37–39], surprisingly, a few others claim that worse. The ethical arguments concerning these trans-
plantations will—and should—take place so that thearguments commonly offered for prohibiting organ sales
are not viable and previous debates should be reopened medical community can find a universal solution. At the
same time, the follow-up care of this particular group offor kidney sales [13, 40]. Still others propose that if ex-
ploitation of donors is avoided and the role of brokers patients should be provided by experienced transplant
physicians following accepted standards of medical care,is omitted, the reward to a donor can be morally justified
[15, 41–43]. In a recent “Nephrology Forum,” Hou sug- in accordance with the basic ethical principles of the
Hippocratic oath.gested that the reward should come from the government
or from a disinterested organization, and as the donor’s
kidney changes the recipient’s life, the reward should be ACKNOWLEDGMENTS
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